Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 3, 2026

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

20.2K

Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock.

R Matyal1, Y Vin, R L Delude

  • 1Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

Intensive Care Medicine
|August 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Critical care medicine·2001
Same author

Tissue factor pathway inhibitor activity in severe sepsis.

Critical care medicine·2001
Same author

Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia.

The Journal of infectious diseases·2001
Same author

The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis.

Critical care medicine·2001
Same author

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.

Blood·2000
Same author

Effects of immune complex formation and complement activation on circulating platelets in the primate.

Clinical immunology (Orlando, Fla.)·1999
Same journal

Rethinking phenotyping in acute respiratory failure: systemic inflammation can be infectious or noninfectious.

Intensive care medicine·2026
Same journal

Letters to the editor or correspondence written opaquely by AI/LLMs: a rising plague in science, but on whose shoulders does the onus of proof lie?

Intensive care medicine·2026
Same journal

Vitamin C in acute critical illness: don't confuse pharmacotherapy and nutrition!

Intensive care medicine·2026
Same journal

Lung- and diaphragm-protective mechanical ventilation in acute respiratory distress syndrome.

Intensive care medicine·2026
Same journal

60 years of ARDS and the evolution of extracorporeal lung support - from ECMO to ECCO<sub>2</sub>R.

Intensive care medicine·2026
Same journal

Publisher Correction: Current knowledge and challenges of sepsis-associated encephalopathy.

Intensive care medicine·2026
See all related articles

Low doses of recombinant human tissue factor pathway inhibitor (TFPI) significantly prolonged survival in a rabbit model of sepsis. These findings suggest lower TFPI doses may be effective in human sepsis trials.

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Infectious Diseases

Background:

  • Sepsis remains a leading cause of mortality worldwide.
  • Effective adjuvant therapies for sepsis are urgently needed.
  • Recombinant human tissue factor pathway inhibitor (TFPI) is a potential therapeutic agent.

Purpose of the Study:

  • To determine the minimum effective dose of recombinant human TFPI for treating septic shock.
  • To evaluate TFPI's efficacy in a rabbit model of Gram-negative bacterial sepsis.

Main Methods:

  • Sepsis was induced in New Zealand white rabbits using Escherichia coli.
  • Animals received gentamicin and were treated with varying doses of TFPI or vehicle.
  • Survival time was the primary outcome measure and analyzed using the Wilcoxen log rank test.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

2.0K

Related Experiment Videos

Last Updated: Apr 3, 2026

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

20.2K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Model of Ischemia and Reperfusion Injury in Rabbits
06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

2.0K

Main Results:

  • The highest TFPI dose (50 µg/kg bolus, 0.5 µg/kg/min infusion) resulted in an average survival time of 118 h compared to 81 h in controls.
  • A significantly lower dose (100 ng/kg bolus, 1.0 ng/kg/min infusion) also prolonged survival to 119 h versus 57 h in controls.
  • Even lower doses showed marginal or no significant survival benefit.

Conclusions:

  • Delayed administration of low-dose recombinant human TFPI effectively prolongs survival in antibiotic-treated Gram-negative bacterial sepsis in rabbits.
  • These results suggest that lower TFPI doses than previously considered may be viable for human sepsis trials.
  • Further research into optimized TFPI dosing for sepsis is warranted.